Following a successful release in the UK, an Israeli company is set to launch its pioneering device for the treatment of premature ejaculation(PE) in Israel, the company, Virility Medical, announced on Tuesday. The device, named in2, is a drug-free intervention for , the most common male sexual health concern and a form of . The company claims that the device - which has undergone clinical testing - extends the duration of sexual intercourse and enhances orgasm.
The in2 device is said to work to immediate effect, and has no adverse side effects or pain. The product has been fully approved by regulatory bodies, including FDA clearance for marketing in the US, CE approval for marketing in Europe, and approval from the Israeli Ministry of Health. Premature ejaculation affects a quarter of men worldwide, and the industry for its treatment is valued at $2.
4 billion. Virility Medical was founded in 2016 in Hod Hasharon by scientists and urologists with a focus on EMS technology research and the development of treatments for premature ejaculation. Virility Medical, led by CEO Sharon Ravid, states that the device is the very first in the world to provide prolonged sexual intercourse for users with Premature Ejaculation (PE).
Such a device, says the company, will improve intimacy between couples. Ravid spoke about the device, saying "[this is] groundbreaking news for millions of men experiencing the common . Current solutions on the market often come with numerous side effects, prolon.
